Showing 1611-1620 of 5771 results for "".
- Pixium Vision Announces the Publication of Peer-Reviewed Clinical Data of the Prima System in Dry AMDhttps://modernod.com/news/pixium-vision-announces-the-publication-of-peer-reviewed-clinical-data-of-the-prima-system-in-dry-amd-i/2481167/Pixium Vision announced the publication of a paper in the Journal of Neural Engineering outlining further data from its Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision, implanted i
- TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for Glaucoma Drug Candidate TC-002https://modernod.com/news/tearclear-announces-positive-topline-results-from-clear-phase-3-study-for-the-treatment-of-glaucoma-with-tc-002-latanoprost-ophthalmic-solution-0005/2481165/TearClear announced that the company’s lead product, TC-002 (latanoprost ophthalmic solution 0.005%), met the primary and all secondary endpoints in the CLEAR phase 3 pivotal trial. With these results, TearClear plans to file a new drug application (NDA) with the FDA in
- Santen Announces Health Canada Approval for Cationorm Plus to Relieve the Symptoms of Dry Eye and Ocular Allergyhttps://modernod.com/news/santen-announces-health-canada-approval-for-cationorm-plus-to-relieve-the-symptoms-of-dry-eye-and-ocular-allergy/2481160/Santen Canada announced the approval of Cationorm Plus by Health Canada. Cationorm Plus is a hydrating artificial tear that restores moisture in the eye to provide long-lasting relief for dry eye and ocular allergy symptoms. “Millions of Canadians are impacted by the dis
- Haag-Streit Announces the Winners of the ‘Slit Lamp Imaging Competition 2022’https://modernod.com/news/haag-streit-announces-the-winners-of-the-slit-lamp-imaging-competition-2022/2481154/Haag-Streit has announced the winners of the ‘Haag-Streit Slit Lamp Imaging Competition 2022.' First place has been awarded to Utpal Sarkar from Disha Eye Hospitals Barrackpore in Kolkata, India. His winning image, taken with a Haag-Streit BX 900 slit lamp imaging sy
- Clearside: Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platformhttps://modernod.com/news/clearside-positive-data-presentations-at-aao-annual-meeting-demonstrate-utility-and-versatility-of-clearside-biomedicals-proprietary-suprachoroidal-space-platform/2481151/Clearside Biomedical announced that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye physicians and surgeons. “These data presenta
- NovaSight Announces FDA 510(K) Clearance of CureSight Digital Therapy for Amblyopiahttps://modernod.com/news/novasight-announces-fda-510k-clearance-of-curesight-digital-therapy-for-amblyopia/2481148/NovaSight announced that the FDA has cleared CureSight, a digital therapy device for amblyopia (lazy eye). CureSight is an eye-tracking-based system aimed for improving visual acuity and stereo acuity by training the visual system to use both eyes simultaneously. The ground-breaking cle
- Kubota Vision Announces Positive Post Hoc Analysis from Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Diseasehttps://modernod.com/news/kubota-vision-announces-positive-post-hoc-analysis-from-phase-3-clinical-trial-of-emixustat-in-patients-with-stargardt-disease/2481147/Kubota Vision announced positive results from a post hoc analysis of the phase 3 clinical trial of the investigational visual cycle modulator emixustat hydrochloride (emixustat) in patients with Stargardt Disease. The primary objective of this study was to determine if emixustat re
- Shore Capital Partners Announces Sale of EyeSouth Partnershttps://modernod.com/news/shore-capital-partners-announces-sale-of-eyesouth-partners/2481146/Shore Capital Partners, a Chicago-based private equity firm, has announced the sale of EyeSouth Partners, an eye care management services organization, to Olympus Partners. Terms of the deal were not disclosed. Shore formed EyeSouth in 2017 with the goal of creating
- Atsena Therapeutics Announces Positive Results from Phase 1/2 Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)https://modernod.com/news/atsena-therapeutics-announces-positive-results-from-phase-iii-clinical-trial-of-atsn-101-for-the-treatment-of-gucy2d-associated-leber-congenital-amaurosis-lca1/2481145/Atsena Therapeutics announced positive results from the phase 1/2 clinical trial of ATSN-101, its lead investigational gene therapy product formerly known as SAR439483, for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data demonstrated that su
- Trefoil Therapeutics Announces Positive Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery Following Descemet Stripping Only (DSO) Surgeryhttps://modernod.com/news/trefoil-therapeutics-announces-positive-phase-2-study-data-showing-corneal-regeneration-and-vision-recovery-following-descemet-stripping-only-dso-surgery/2481137/Trefoil Therapeutics announced positive phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy (FECD). TTHX1114, a proprietary engineered fibroblast growth factor-1 (FGF1) variant, is delivered as an intracameral injection into the anterior chamber of the eye. Most